These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 35270708)
21. Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients. Macesic N; Laplante JM; Aaron JG; DiMango EA; Miko BA; Pereira MR; Reshef R; St George K Transpl Infect Dis; 2021 Jun; 23(3):e13542. PubMed ID: 33278052 [TBL] [Abstract][Full Text] [Related]
22. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Salvatore M; Laplante JM; Soave R; Orfali N; Plate M; van Besien K; St George K Transpl Infect Dis; 2020 Aug; 22(4):e13336. PubMed ID: 32449254 [TBL] [Abstract][Full Text] [Related]
23. Baloxavir marboxil (Xofluza) for treatment of influenza. Med Lett Drugs Ther; 2018 Dec; 60(1561):193-196. PubMed ID: 30653474 [No Abstract] [Full Text] [Related]
24. Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review. Abed Y; Saim-Mamoun A; Boivin G Rev Med Virol; 2021 May; 31(3):e2175. PubMed ID: 32975358 [TBL] [Abstract][Full Text] [Related]
25. Retracted and republished from: "The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs". Li Y; Huo S; Yin Z; Tian Z; Huang F; Liu P; Liu Y; Yu F mBio; 2024 May; 15(5):e0017524. PubMed ID: 38551343 [TBL] [Abstract][Full Text] [Related]
26. The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs. Li Y; Huo S; Yin Z; Tian Z; Huang F; Liu P; Liu Y; Yu F mBio; 2023 Oct; 14(5):e0127323. PubMed ID: 37610204 [TBL] [Abstract][Full Text] [Related]
27. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172 [TBL] [Abstract][Full Text] [Related]
28. Association of baloxavir marboxil prescription with subsequent medical resource utilization among school-aged children with influenza. Takeuchi M; Kawakami K Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):779-786. PubMed ID: 33608939 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of single-dose antiviral drugs for influenza treatment: A systematic review and network meta-analysis. Zhao Y; Huang G; He W; Sun Q; Zhao X; Li D; Wang H; Cui W; Liu X J Med Virol; 2022 Jul; 94(7):3270-3302. PubMed ID: 35315516 [TBL] [Abstract][Full Text] [Related]
30. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018. Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection. Ando Y; Noshi T; Sato K; Ishibashi T; Yoshida Y; Hasegawa T; Onishi M; Kitano M; Oka R; Kawai M; Yoshida R; Sato A; Shishido T; Naito A J Antimicrob Chemother; 2021 Jan; 76(1):189-198. PubMed ID: 33035324 [TBL] [Abstract][Full Text] [Related]
32. Antivirals--current trends in fighting influenza. Król E; Rychłowska M; Szewczyk B Acta Biochim Pol; 2014; 61(3):495-504. PubMed ID: 25180220 [TBL] [Abstract][Full Text] [Related]
33. Antiviral drugs for influenza. Med Lett Drugs Ther; 2020 Jan; 62(1589):1-4. PubMed ID: 31999661 [No Abstract] [Full Text] [Related]
34. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Ikematsu H; Kawai N Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296 [TBL] [Abstract][Full Text] [Related]
35. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza. Shirley M Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915 [TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials. Kuo YC; Lai CC; Wang YH; Chen CH; Wang CY J Microbiol Immunol Infect; 2021 Oct; 54(5):865-875. PubMed ID: 34020891 [TBL] [Abstract][Full Text] [Related]
37. Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan. Yoshimura Y; Sasaki H; Horiuchi H; Miyata N; Kawakami C; Usuku S; Tachikawa N Eur J Clin Microbiol Infect Dis; 2020 Sep; 39(9):1637-1640. PubMed ID: 32291543 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of baloxavir marboxil compared to laninamivir for the treatment of influenza in Japan. Skrzeczek A; Ikeoka H; Hirotsu N; Ansaripour A; Aballéa S; Onishi Y; Hill M; Igarashi A J Infect Chemother; 2021 Feb; 27(2):296-305. PubMed ID: 33243614 [TBL] [Abstract][Full Text] [Related]
39. [Present and future in development of new anti-influenza drugs]. Watanabe A Nihon Rinsho; 2010 Sep; 68(9):1685-9. PubMed ID: 20845748 [TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan. Dronova M; Ikeoka H; Itsumura N; Hirotsu N; Ansaripour A; Aballéa S; Onishi Y; Hill M; Igarashi A Curr Med Res Opin; 2021 Jul; 37(7):1135-1148. PubMed ID: 33858277 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]